Sign in
CompletedNo phase

Optimizing Vancomycin Therapy in Children

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Philadelphia, United StatesSee the site
Trial code
Status
Completed
People taking part
29 people enrolled
Started
12 Dec 2022
Ended
22 Nov 2023
Type of study
Observational
Record updated
20 December 2024

Who can take part

Age
1 year to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Administered intravenous vancomycin via intermittent infusion,
  • Eligible for vancomycin AUC monitoring, per the subject's clinical team, and
  • Parental/guardian permission (informed consent)

Who cannot take part

  • Receipt of renal replacement therapy, plasmapheresis, or extracorporeal membrane oxygenation (ECMO), or
  • Unable to provide urine and blood samples

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United States

About the trial

What the trial wants to find out

The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under the curve (AUC) in critically ill children.

The group in the trial

  • Study Cohort

    Recipients of vancomycin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
20 December 2024